Product Details
KISSH SARS-CoV-2 Neutralizing Antibodies Detection Kit (ELISA)
Test Principle
The SARS-COV-2 Neutralizing Antibody Detection Kit (ELISA) adopts the enzyme-linked immune method to simulate the virus
neutralization process to qualitative analyze the new coronavirus neutralizing antibody in human blood samples. The kit contains two key components: HRP labeled
recombinant SARS-COV-2 RBD protein (HRP-RBD) and human ACE-2
receptor protein (ACLi-2). Firstly, after the sample and quality
control sample were pre incubated with hrp-rbd, the neutralizing
antibody of the sample was combined with HRP-RBD to form a mixture of neutralizing antibodies.Then the mixture was added to
the enzyme plate pre coated with ACE-2 protein and incubated for a
period of time. The unbound 1IRP-R13D and the bound with non neutralizing antibody will bind to ACE-2 protein on the plate,
while the mixture of neutralizing antibody will be removed during
washing. After the washing step, TMB solution is added. After a
period of reaction, the color turns blue. After the termination solution is added, the color turns
yellow and the value is read and calculated. The higher the content of SARS-CoV-2 neutralizing antibody in the sample, the
lighter the color; the lower the content, the darker the color.
Intended Use
SARS-CoV-2 Neutralizing Antibodies Detection Kit (ELISA) is used
for qualitative detection of theneutralizing antibody in human
serum or plasma sample. It adopts the enzyme-linked immune method
to simulate the virus neutralization process to qualitative analyze
the new coronavirus neutralizing antibody in human blood samples.
Note: For medical professional use only.
Company Profile
Shenzhen Kisshealh Biotechnology Co., Ltd., located in the Pingshan
District, Shenzhen, P.R. China. is a diagnostics company focused on
the development and manufacture of IVD tests at the Point-of-Care
with highly innovative proprietary technology.
We focused on the emerging markets of in vitro pathological
diagnosis and immunodiagnosis. We developed, manufactured and
successfully launched the in vitro immunodiagnosis platform for
cancer and the POCT for infectious, genetic and chronic diseases.
<span style="color: rgb(33, 33, 33); text-transform: none;
text-indent: 0px; letter-spacing: normal;" initial;"="" initial;=""
0px;="" normal;="" 255);="" 255,="" rgb(255,="" 2;=""
!important;="" inline="" none;="" 600;="" 14px;="" sans-serif;=""
arial,="" roboto,="" w3",="" gb="" sans="" "hiragino="" gb",=""
hei",="" micro="" "wenquanyi="" sans",="" "droid="" arimo,=""
freesans,="" yahei",="" "microsoft="" helvetica,="" grande",=""
"lucida="" ui",="" segoe="">At Kissh we work every day to shape
the future of in-vitro diagnostic testing. And our people are our
best asset, the reason for our track record and our strength while
we are moving forward. We live by our fundamental values and
incorporate them in everything that we do. Our best asset is ‘Step
Forward Every Second’